First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs. approximately 35% with CCTA alone. GAMEFILM data highlight high prevalence
MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it will release
SAN FRANCISCO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced late-breaking one-year
SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the
Heartflow Plaque StagingTM, the only staging tool based on total plaque volume*, is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility of
Issued on behalf of Ventripoint Diagnostics Ltd.As the number of people living with congenital heart disease climbs and most patients in poorer regions go without timely care, a Toronto-based AI imaging company is
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended
VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global AI cardiology market is on track to hit $2.78 billion this year and climb past $14 billion by 2034, and the
